Montreal, QC November 17, 2003 – Celmed BioSciences, a subsidiary of Theratechnologies that targets niche applications in oncology and neurology, has announced three senior scientific appointments.
The company says it has created three new vice president positions: Dr Pierre A Caudrelier will assume the position of vice president, clinical affairs, while Dr Pascal Puchois, PharmD, DSc, will become vice president, preclinical research and technologies. Raphaela (Ela) Borenstein, MSc, MBA, will assume the position of vice president, regulatory affairs and product strategy.
Dr Caudrelier obtained his degree in medicine from University of Paris VI (Piti-Salptrire Hospital) and holds a degree in applied epidemiology from the Universities of Tours and Bordeaux II. He has acquired sound clinical expertise with major pharmaceutical and biopharmaceutical companies. During the past 15 years, he held various senior positions in the clinical field with Pasteur Mrieux Connaught and Aventis Pasteur in Lyon (France) and North York (Ontario). Before joining Celmed, he successively held the positions of vice president, scientific and medical affairs of IDM Biotech and general manager of its Canadian subsidiary IDM-Biotech Ltd.
Dr Puchois will oversee laboratory activities as well as research collaborations. He is a pharmacist, a biologist and holds a PhD in pharmaceutical sciences. Dr Puchois began his career as a researcher at the Institut Pasteur with Pr JC Fruchart (Lille, France), then at various research laboratories, at the INSERM (France), the NIH (US) and the CNRS (Nice, France). Since 1988, Dr Puchois has created and managed several European contract research organizations with a special focus on integration of laboratory activities to support preclinical and clinical research. Before joining Celmed, he was acting CEO at Bio-Inova Life Sciences International in Montreal.
Ms Borenstein holds an executive MBA specializing in bio-industry from the Universit du Qubec Montral as well as an MSc in pharmacology from the University of Toronto. She has held several management positions in the biotechnology and pharmaceutical sectors, including vice president, regulatory and clinical affairs with Theratechnologies. Prior to that, she held positions of increasing responsibility, ultimately senior vice president, scientific affairs with Technilab.
Have your say: